www.ibtimes.co.uk JPMorgan Forecast Over 85% Upside for Two Biopharma Stocks Targeting Obesity and Chronic Conditions
The two biopharma firms have developed drug candidates to treat autoimmune and pulmonary diseases. They have demonstrated good safety profiles and efficacy in various stages of clinical trials.
Next
innovai @lemmy.world
Posts 1
Comments 0